ATE457727T1 - Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen - Google Patents

Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen

Info

Publication number
ATE457727T1
ATE457727T1 AT06760628T AT06760628T ATE457727T1 AT E457727 T1 ATE457727 T1 AT E457727T1 AT 06760628 T AT06760628 T AT 06760628T AT 06760628 T AT06760628 T AT 06760628T AT E457727 T1 ATE457727 T1 AT E457727T1
Authority
AT
Austria
Prior art keywords
combination
imatinib
pyrimidylaminobensamide
prevention
compounds
Prior art date
Application number
AT06760628T
Other languages
English (en)
Inventor
Leila Alland
Paul Manley
Juergen Mestan
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE457727T1 publication Critical patent/ATE457727T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT06760628T 2005-06-03 2006-06-02 Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen ATE457727T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68775805P 2005-06-03 2005-06-03
PCT/US2006/021307 WO2006132930A1 (en) 2005-06-03 2006-06-02 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Publications (1)

Publication Number Publication Date
ATE457727T1 true ATE457727T1 (de) 2010-03-15

Family

ID=36968749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06760628T ATE457727T1 (de) 2005-06-03 2006-06-02 Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen

Country Status (27)

Country Link
US (2) US7767688B2 (de)
EP (1) EP1893213B1 (de)
JP (2) JP5281887B2 (de)
KR (1) KR101276425B1 (de)
CN (1) CN101180060B (de)
AT (1) ATE457727T1 (de)
AU (1) AU2006255559B2 (de)
BR (1) BRPI0611506A2 (de)
CA (1) CA2608814C (de)
CY (1) CY1110027T1 (de)
DE (1) DE602006012313D1 (de)
DK (1) DK1893213T3 (de)
ES (1) ES2339593T3 (de)
HK (1) HK1115528A1 (de)
HR (1) HRP20100265T1 (de)
IL (1) IL187408A0 (de)
MA (1) MA29565B1 (de)
MX (1) MX2007015159A (de)
NO (1) NO20080037L (de)
NZ (1) NZ563446A (de)
PL (1) PL1893213T3 (de)
PT (1) PT1893213E (de)
RU (1) RU2430727C2 (de)
SI (1) SI1893213T1 (de)
TN (1) TNSN07453A1 (de)
WO (1) WO2006132930A1 (de)
ZA (1) ZA200709473B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611506A2 (pt) * 2005-06-03 2010-09-14 Novartis Ag Combinação de compostos pirimidilaminobenzamida e imatinib para tratar ou prevenir doenças proliferativas
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
EP2382976A1 (de) * 2010-04-30 2011-11-02 Hiroshima University Verwendung von PDGF-R-Inhibitoren zur Behandlung der Lymphknotenmetastasen von Magenkrebs
CN102719530B (zh) * 2012-05-07 2013-11-06 厦门艾德生物医药科技有限公司 一种用于检测PDGFRα基因突变的引物、探针及试剂盒
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
US20200206223A1 (en) 2017-07-26 2020-07-02 Ftf Pharma Private Limited Liquid dosage forms of imatinib
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
BRPI0611506A2 (pt) * 2005-06-03 2010-09-14 Novartis Ag Combinação de compostos pirimidilaminobenzamida e imatinib para tratar ou prevenir doenças proliferativas

Also Published As

Publication number Publication date
JP2013035853A (ja) 2013-02-21
KR101276425B1 (ko) 2013-06-19
US20100190800A1 (en) 2010-07-29
PL1893213T3 (pl) 2010-08-31
US8653093B2 (en) 2014-02-18
AU2006255559A1 (en) 2006-12-14
JP2008542390A (ja) 2008-11-27
DK1893213T3 (da) 2010-06-07
BRPI0611506A2 (pt) 2010-09-14
HK1115528A1 (en) 2008-12-05
HRP20100265T1 (hr) 2010-06-30
WO2006132930A1 (en) 2006-12-14
RU2430727C2 (ru) 2011-10-10
CN101180060B (zh) 2011-12-28
EP1893213A1 (de) 2008-03-05
TNSN07453A1 (en) 2009-03-17
AU2006255559B2 (en) 2009-12-17
NO20080037L (no) 2008-01-03
NZ563446A (en) 2011-02-25
CA2608814A1 (en) 2006-12-14
US7767688B2 (en) 2010-08-03
US20080312252A1 (en) 2008-12-18
MX2007015159A (es) 2008-02-15
RU2007147957A (ru) 2009-07-20
SI1893213T1 (sl) 2010-05-31
PT1893213E (pt) 2010-04-19
JP5281887B2 (ja) 2013-09-04
KR20080021633A (ko) 2008-03-07
CA2608814C (en) 2013-09-03
ZA200709473B (en) 2008-12-31
CN101180060A (zh) 2008-05-14
MA29565B1 (fr) 2008-06-02
IL187408A0 (en) 2011-07-31
DE602006012313D1 (de) 2010-04-01
CY1110027T1 (el) 2015-01-14
ES2339593T3 (es) 2010-05-21
EP1893213B1 (de) 2010-02-17

Similar Documents

Publication Publication Date Title
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
DE602007005120D1 (de) 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist
DE602005017373D1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
ATE457727T1 (de) Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
TW200628473A (en) Novel heterocycles
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
ATE462438T1 (de) Verwendung von carrageenan zur behandlung von rhinovirus-infektionen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
DE602005014624D1 (de) Verbindungen zur behandlung von krankheiten
ATE514429T1 (de) Mittel zur behandlung von mastitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1893213

Country of ref document: EP